A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes

Sweet, David G., Turner, Mark, Straňák, Zbynek, Plavka, Richard, Clarke, Paul, Stenson, Ben, Singer, Dominique, Goelz, Rangmar, Fabbri, Laura, Varoli, Guido, Piccinno, Annalisa, Santoro, Debora, Del Buono, Dorothea and Speer, Christian P. (2022) A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes. Journal of Maternal-Fetal & Neonatal Medicine, 35 (24). pp. 4739-4742. ISSN 1476-4954

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (993kB) | Preview

Abstract

Objective: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27 +0 to 33 +6 weeks’ gestation who were treated in a first-in-human study with a new fully synthetic surfactant (CHF5633) enriched with SP-B and SP-C proteins.  Outcome measures: Children were assessed using Bayley Scales of Infant Development (BSID), with a score below normal defined as BSID-II Mental Development Index score <70, or BSID-III cognitive composite score <85. In addition, a health status questionnaire was used to check for functional disability including respiratory problems and related treatments, sensory and neurodevelopment assessments, communication skills as well as the number of hospitalizations.  Results: 35 of 39 survivors had a neurodevelopmental assessment, 24 infants being evaluated by Bayley’s Scales and 11 by health status questionnaires only. 23 children had scores within normal limits and one had BSID-III <85. The remaining 11 were judged clinically to have normal development. Health status questionnaires detected only issues that would normally be expected in preterm-born children.  Conclusions: This assessment offers reassurance that treatment with CHF5633 surfactant was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years corrected age.

Item Type:	Article
Uncontrolled Keywords:	24-month developmental assessment,synthetic surfactant,first-in-human study,respiratory distress syndrome,pediatrics, perinatology, and child health,obstetrics and gynaecology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2735
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	05 Jan 2021 00:56
Last Modified:	06 Feb 2025 09:34
URI:	https://ueaeprints.uea.ac.uk/id/eprint/78032
DOI:	10.1080/14767058.2020.1863363

Downloads

Actions (login required)

View Item